Phio Pharmaceuticals regains Nasdaq minimum bid price compliance after reverse split

Phio Pharmaceuticals Corp.

Received Nasdaq notice on July 19, 2024, confirming compliance with Listing Rule 5550(a)(2).
Compliance achieved after 1-for-9 reverse stock split effective July 5, 2024.
Company continues trading on Nasdaq Capital Market; delisting risk removed.

item 8.01

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-24-005049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.